These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 30854618)
1. Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center. Nakano M; Karasawa K; Moriyama T; Uchida K; Nitta K Clin Exp Nephrol; 2019 Jun; 23(6):852-858. PubMed ID: 30854618 [TBL] [Abstract][Full Text] [Related]
2. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation. Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G; Nephron; 2020; 144(4):195-203. PubMed ID: 32050203 [TBL] [Abstract][Full Text] [Related]
4. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G; Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851 [TBL] [Abstract][Full Text] [Related]
5. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ; J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465 [TBL] [Abstract][Full Text] [Related]
6. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Sethi S; Fervenza FC Semin Nephrol; 2011 Jul; 31(4):341-8. PubMed ID: 21839367 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features of membranoproliferative glomerulonephritis under a new classification. Nargund P; Kambham N; Mehta K; Lafayette RA Clin Nephrol; 2015 Dec; 84(6):323-30. PubMed ID: 26445002 [TBL] [Abstract][Full Text] [Related]
8. Membranoproliferative glomerulonephritis: current histopathological classification, clinical profile, and kidney outcomes. Bernardes TP; Mastroianni-Kirsztajn G J Bras Nefrol; 2023; 45(1):45-50. PubMed ID: 35789244 [TBL] [Abstract][Full Text] [Related]
9. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Noris M; Donadelli R; Remuzzi G Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306 [TBL] [Abstract][Full Text] [Related]
10. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents. Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151 [TBL] [Abstract][Full Text] [Related]
11. Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis. Kawasaki Y; Kanno S; Ono A; Suzuki Y; Ohara S; Sato M; Suyama K; Hashimoto K; Hosoya M Pediatr Nephrol; 2016 Jul; 31(7):1091-9. PubMed ID: 26846787 [TBL] [Abstract][Full Text] [Related]
12. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis. Gupta N; Wakefield DN; Clapp WL; Garin EH Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516 [TBL] [Abstract][Full Text] [Related]
14. Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification. Alasfar S; Carter-Monroe N; Rosenberg AZ; Montgomery RA; Alachkar N BMC Nephrol; 2016 Jan; 17():7. PubMed ID: 26754737 [TBL] [Abstract][Full Text] [Related]
15. Histopathology of MPGN and C3 glomerulopathies. Cook HT; Pickering MC Nat Rev Nephrol; 2015 Jan; 11(1):14-22. PubMed ID: 25447133 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy. Kovala M; Seppälä M; Räisänen-Sokolowski A; Meri S; Honkanen E; Kaartinen K Cells; 2023 Feb; 12(5):. PubMed ID: 36899849 [TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Bomback AS; Appel GB Nat Rev Nephrol; 2012 Nov; 8(11):634-42. PubMed ID: 23026947 [TBL] [Abstract][Full Text] [Related]
18. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476 [TBL] [Abstract][Full Text] [Related]
19. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Licht C; Fremeaux-Bacchi V Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809 [TBL] [Abstract][Full Text] [Related]
20. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III. West CD; McAdams AJ Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]